Objectives: At the conclusion of this program, participants should be able to: 1. Review the current epidemiologic trends related to Hepatitis C in the U.S. and in WV. 2. Understand the mechanism of action for the three classes of direct-acting antivirals (DAAs) available for the treatment of chronic hepatitis C. 3. Know the two pieces of clinical information that is required to recommend appropriate antiviral regimens for chronic Hepatitis C outlined in the IDSA/AASLD chronic hepatitis C management guidelines. 4. Describe the most common drug-drug interactions with the DAAs available for the treatment of chronic hepatitis C. 5. Describe effective harm-reduction messaging aimed at individuals at risk for, or infected with, chronic Hepatitis C.

Information concerning faculty, speaker and planning committee relationships will be available on site and disclosed to the audience from the podium. The presenter has disclosed that no commercial relationships exist.